Skip to main content

New Management Options for End-Stage Chronic Liver Disease and Acute Liver Failure

Potential for Pediatric Patients

Pediatric Drugs volume 8, pages 1–13 (2006)Cite this article

Abstract

The management of children with end-stage chronic liver disease and acute liver failure mandates a multidisciplinary approach and intense monitoring. In recent years, considerable progress has been made in developing specific and supportive medical measures, but studies and publications have mainly concerned adult patients. Therapeutic approaches to complications of end-stage chronic liver disease and acute liver failure (e.g. refractory ascites, hepatorenal syndrome, encephalopathy, and cerebral edema) that may be applied to children are reviewed in this article.

Mild-to-moderate ascites should be managed by modest salt restriction and oral diuretic therapy in the first instance. Large volume paracentesis associated with colloid volume expansion and diuretic therapy may be effective for acute relief. Treatment of hepatorenal syndrome type 1 with vasopressin analogs (terlipressin) is recommended prior to liver transplantation in order to improve renal function. Prevention and treatment of chronic hepatic encephalopathy are directed primarily at controlling the events that may precipitate hepatic encephalopathy and at reducing ammonia generation and increasing its detoxification or removal. In addition to reduction of gut ammonia production using non-absorbable disaccharides such as lactulose and/or antibacterials such as neomycin, sodium benzoate may be used on a long-term basis to prevent, stabilize, or improve hepatic encephalopathy. The management of hepatic encephalopathy in acute liver failure is considerably more unsatisfactory; treatment is aimed at preventing brain edema and intracranial hypertension. Extracorporeal liver support devices are now used commonly in critically ill children with acute renal failure, advanced hepatic encephalopathy, cerebral edema, intracranial hypertension, and severe coagulopathy. Continuous renal replacement therapy could potentially help support patients until liver transplantation is performed or liver regeneration occurs. The Molecular Adsorbent Recirculating System (MARS® or albumin dialysis) is the liver support system most frequently used worldwide in adults and appears to offer distinct advantages over hepatocyte-based systems.

There are no specific medical therapies or devices that can correct all of the functions of the liver. Apart from a few metabolic diseases presenting with severe liver dysfunction for which specific medical therapies may preclude the need for liver transplantation, liver transplantation still remains the only definitive therapy in most instances of end-stage chronic liver disease and acute liver failure. Future research should focus on gaining a better understanding of the mechanisms responsible for liver cell death and liver regeneration, as well as developments in hepatocyte transplantation and liver-directed gene therapy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Table II
Fig. 1
Table III
Fig. 2

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Kelly DA. Current results and evolving indications for liver transplantation in children. J Pediatr Gastroenterol Nutr 1998; 27(2): 214–21

    PubMed  Article  CAS  Google Scholar 

  2. Goss JA, Shackleton CR, McDiarmid SV, et al. Long-term results of pediatric liver transplantation: an analysis of 569 transplants. Ann Surg 1998; 228(3): 411–20

    PubMed  Article  CAS  Google Scholar 

  3. Durand P, Debray D, Mandel R, et al. Acute liver failure in infancy: a 14-year experience of a pediatric liver transplantation center. J Pediatr 2001; 139(6): 871–6

    PubMed  Article  CAS  Google Scholar 

  4. Devictor D, Desplanques L, Debray D, et al. Emergency liver transplantation for fulminant hepatic failure in infants and children. Hepatology 1992; 16(5): 1156–62

    PubMed  Article  CAS  Google Scholar 

  5. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38(1): 258–66

    PubMed  Article  Google Scholar 

  6. Ginès P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123(6): 1839–47

    PubMed  Article  Google Scholar 

  7. Sanyal AJ, Genning C, Reddy RK, et al. The North American Study of Treatment for Refractory Ascites (NASTRA). Gastroenterology 2003; 124(3): 634–41

    PubMed  Article  Google Scholar 

  8. Heyman MB, Laberge JM. Role of transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension in pediatric patients. J Pediatr Gastroenterol Nutr 1999; 29(3): 240–9

    PubMed  Article  CAS  Google Scholar 

  9. Huppert PE, Goffette P, Astfalk W, et al. Transjugular intrahepatic portosystemic shunts in children with biliary atresia. Cardiovasc Intervent Radiol 2002; 25(6): 484–93

    PubMed  Article  Google Scholar 

  10. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002; 97(8): 2046–50

    PubMed  Article  Google Scholar 

  11. Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis: International Ascites Club. Hepatology 1996; 23(1): 164–76

    PubMed  Article  CAS  Google Scholar 

  12. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38Suppl. 1: S69–89

    PubMed  Article  Google Scholar 

  13. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993; 105(1): 229–36

    PubMed  Google Scholar 

  14. Ginès P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet 2003; 362(9398): 1819–27

    PubMed  Article  Google Scholar 

  15. Ellis D, Avner ED, Starzl TE. Renal failure in children with liver failure undergoing liver transplantation. J Pediatr 1986; 108(3): 393–8

    PubMed  Article  CAS  Google Scholar 

  16. Van Roey G, Moore K. The hepatorenal syndrome. Pediatr Nephrol 1996; 10(1): 100–7

    PubMed  Google Scholar 

  17. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004; 40(1): 140–6

    PubMed  Article  Google Scholar 

  18. McDiarmid SV. Renal function in pediatric liver transplant patients. Kidney Int Suppl 1996; 53: S77–84

    PubMed  CAS  Google Scholar 

  19. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36 (4 Pt 1): 941–8

    PubMed  CAS  Google Scholar 

  20. Pomier-Layrargues G, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003; 38(1): 238–43

    PubMed  Article  CAS  Google Scholar 

  21. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122(4): 923–30

    PubMed  Article  CAS  Google Scholar 

  22. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30(4): 870–5

    PubMed  Article  CAS  Google Scholar 

  23. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002; 36(2): 374–80

    PubMed  Article  CAS  Google Scholar 

  24. Guevara M, Ginès P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28(2): 35–41

    Article  Google Scholar 

  25. Brensing KA, Textor J, Perz J, et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non transplant patients with hepatorenal syndrome: a phase II study. Gut 2000; 47(2): 288–95

    PubMed  Article  CAS  Google Scholar 

  26. Testino G, Ferro C, Sumberaz A, et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003; 50(54): 1753–5

    PubMed  Google Scholar 

  27. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993; 21(3): 328–38

    PubMed  Article  CAS  Google Scholar 

  28. Davenport A. Is there a role for continuous renal replacement therapies in patients with liver and renal failure? Kidney Int 1999; 56Suppl. 72: S62–6

    Article  Google Scholar 

  29. Mitzner S, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized, controlled clinical trial. Liver Transpl 2000; 6(3): 277–86

    PubMed  Article  CAS  Google Scholar 

  30. Jalan R, Shawcross D, Davies N. The molecular pathogenesis of hepatic encephalopathy. Int J Biochem Cell Biol 2003; 35(9): 1175–81

    PubMed  Article  CAS  Google Scholar 

  31. Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis 1996; 16(3): 329–38

    PubMed  Article  CAS  Google Scholar 

  32. Butterworth RF. Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices. Liver Int 2003; 23Suppl. 3: 5–9

    PubMed  Article  CAS  Google Scholar 

  33. Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol 2002; 7(1): 27–35

    PubMed  Article  CAS  Google Scholar 

  34. Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double blind randomized trial. Hepatology 1992; 16(1): 138–44

    PubMed  Article  CAS  Google Scholar 

  35. Malaguarnera M, Pistone G, Astuto M, et al. L-carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig Dis 2003; 21(3): 271–5

    PubMed  Article  Google Scholar 

  36. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study. Hepatology 1997; 25: 1351–60

    PubMed  Article  CAS  Google Scholar 

  37. Jalan R, Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut 2003; 52(7): 1041–5

    PubMed  Article  CAS  Google Scholar 

  38. Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond) 2004; 106: 467–74

    Article  CAS  Google Scholar 

  39. Riordan SM, Williams R. Acute liver failure: targeted artificial and hepatocyte-based support of liver regeneration and reversal of multiorgan failure. J Hepatol 2000; 32Suppl. 1: 63–76

    PubMed  Article  CAS  Google Scholar 

  40. Kjaergard LL, Liu J, Ais-Nielsen B, et al. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003; 289(2): 217–22

    PubMed  Article  Google Scholar 

  41. O’Grady JG, Gimson AES, O’Brien CJ, et al. Controlled trials of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94 (5 Pt 1): 1186–92

    PubMed  Google Scholar 

  42. Singer AL, Olthoff KM, Kim H, et al. Role of plasmapheresis in the management of acute hepatic failure in children. Ann Surg 2001; 234(3): 418–24

    PubMed  Article  CAS  Google Scholar 

  43. Matsubara AS, Okabe K, Ouchi K, et al. Continuous removal of middle molecules by hemofiltration in patients with acute liver failure. Crit Care Med 1990; 18(12): 1331–8

    PubMed  Article  CAS  Google Scholar 

  44. Hammer GB, So SKS, Al-Uzri A, et al. Continuous venovenous hemofiltration with dialysis in combination with total hepatectomy and portocaval shunting. Transplantation 1996; 62(1): 130–2

    PubMed  Article  CAS  Google Scholar 

  45. Kubota T, Sekido H, Morioka D, et al. Acute hepatic failure with deep hepatic coma treated successfully by high-flow continuous hemodiafiltration and living-donor liver transplantation: a case report. Transplant Proc 2003; 35(1): 394–6

    PubMed  Article  CAS  Google Scholar 

  46. Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28: 3581–7

    PubMed  Article  CAS  Google Scholar 

  47. Mitzner S, Stange J, Klammt S, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12Suppl. 17: S75–82

    PubMed  CAS  Google Scholar 

  48. Sen S, Mookerjee P, Davies A, et al. Review article: the Molecular Adsorbent Recirculating System (MARS) in liver failure. Aliment Pharmacol Ther 2002; 16Suppl. 5: 32–8

    PubMed  Article  CAS  Google Scholar 

  49. Heemann U, Treichel U, Philipp T, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36 (4 Pt 1): 949–58

    PubMed  CAS  Google Scholar 

  50. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002; 22Suppl. 2: 20–5

    PubMed  CAS  Google Scholar 

  51. Hommann M, Kasakow LB, Geoghegan J, et al. Application of MARS artificial liver support as bridging therapy before split liver retransplantation in a 15-month-old child. Pediatr Transplant 2002; 6(4): 340–3

    PubMed  Article  CAS  Google Scholar 

  52. Shi Y, He J, Chen S, et al. MARS: optimistic therapy method in fulminant hepatic failure secondary to cytotoxic mushroom poisoning: a case report. Liver 2002; 22Suppl. 2: 78–80

    PubMed  Google Scholar 

  53. Covic A, Goldsmith DJ, Gusbeth-Tatomir P, et al. Successful use of Molecular Absorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. Liver Int 2003; 23Suppl. 3: 21–7

    PubMed  Article  CAS  Google Scholar 

  54. Prokurat S, Grenda R, Lipowski D, et al. MARS procedure as a bridge to combined liver-kidney transplantation in severe chromium-copper acute intoxication: a paediatric case report. Liver 2002; 22Suppl. 2: 76–7

    PubMed  Google Scholar 

  55. Tissieres P, Sasbon JS, Devictor D. Liver support for fulminant hepatic failure: is it time to use the molecular adsorbents recycling system in children? Pediatr Crit Care Med 2005; 6(5): 585–91

    PubMed  Article  Google Scholar 

  56. Ash SR. Extracorporeal blood detoxification by sorbents in treatment of hepatic encephalopathy. Adv Ren Replace Ther 2002; 9(1): 3–18

    PubMed  Article  Google Scholar 

  57. Watanabe FD, Mullon CJP, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure: a phase I clinical trial. Ann Surg 1997; 225(5): 484–94

    PubMed  Article  CAS  Google Scholar 

  58. Millis JM, Cronin DC, Johnson R, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation 2002; 74(12): 1735–46

    PubMed  Article  Google Scholar 

  59. Samuel D, Ichai P, Feray C, et al. Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation 2002; 73(2): 257–64

    PubMed  Article  CAS  Google Scholar 

  60. Demetriou AA, Brown Jr RS, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239(5): 660–7

    PubMed  Article  Google Scholar 

  61. Pitkin Z, Mullon C. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif Organs 1999; 23(9): 829–33

    PubMed  Article  CAS  Google Scholar 

  62. Murray KF, Kowdley KV. Neonatal hemochromatosis. Pediatrics 2001; 108(4): 960–4

    PubMed  Article  CAS  Google Scholar 

  63. Silver MM, Beverley DW, Valberg LS, et al. Perinatal hemochromatosis: clinical, morphologic, and quantitative iron studies. Am J Pathol 1987; 128(3): 538–54

    PubMed  CAS  Google Scholar 

  64. Sigurdsson L, Reyes J, Kocochis SA, et al. Neonatal hemochromatosis: outcomes of pharmacologic and surgical therapies. J Pediatr Gastroenterol Nutr 1998; 26(1): 85–9

    PubMed  Article  CAS  Google Scholar 

  65. Goldfischer S, Grotsky HW, Chang CH, et al. Idiopathic neonatal iron storage involving the liver, pancreas, heart, and endocrine and exocrine glands. Hepatology 1981; 1(1): 58–64

    PubMed  Article  CAS  Google Scholar 

  66. Vohra P, Haller C, Emre S, et al. Neonatal hemochromatosis: the importance of early recognition of liver failure. J Pediatr 2000; 136(4): 537–41

    PubMed  Article  CAS  Google Scholar 

  67. Shneider BL, Setchell KD, Whitington PF, et al. Delta4-3-oxosteroid 5beta-reductase deficiency causing neonatal liver failure and hemochromatosis. J Pediatr 1994; 124(2): 234–8

    PubMed  Article  CAS  Google Scholar 

  68. Siafakas CG, Jonas MM, Perez-Atayde AR. Abnormal bile acid metabolism and neonatal hemochromatosis: a subset with poor prognosis. J Pediatr Gastroenterol Nutr 1997; 25(3): 321–6

    PubMed  Article  CAS  Google Scholar 

  69. Rand EB, McClenathan DT, Whitington PF. Neonatal hemochromatosis: report of successful orthotopic liver transplantation. J Pediatr Gastroenterol Nutr 1992; 15(3): 325–9

    PubMed  Article  CAS  Google Scholar 

  70. Lund DP, Lillehei CW, Kevy S, et al. Liver transplantation in newborn liver failure: treatment for neonatal hemochromatosis. Transplant Proc 1993; 25 (1 Pt 2): 1068–71

    PubMed  CAS  Google Scholar 

  71. Muiesan P, Rela M, Kane P, et al. Liver transplantation for neonatal haemochromatosis. Arch Dis Child Fetal Neonatal Ed 1995; 73(3): F178–80

    PubMed  Article  CAS  Google Scholar 

  72. Bonatti H, Muiesan P, Connelly S, et al. Hepatic transplantation in children under 3 months of age: a single centre’s experience. J Pediatr Surg 1997; 32(3): 486–8

    PubMed  Article  CAS  Google Scholar 

  73. Flynn DM, Mohan N, McKiernan P, et al. Progress in treatment and outcome for children with neonatal haemochromatosis. Arch Dis Child Fetal Neonatal Ed 2003; 88(2): F124–7

    PubMed  Article  CAS  Google Scholar 

  74. Shamieh I, Kibort PK, Suchy FJ, et al. Antioxidant therapy for neonatal iron storage disease [abstract]. Pediatr Res 1993; 33: 109A

    Google Scholar 

  75. Colletti RB, Clemmons JJ. Familial neonatal hemochromatosis with survival. J Pediatr Gastroenterol Nutr 1988; 7(1): 39–45

    PubMed  Article  CAS  Google Scholar 

  76. Muller-Berghaus J, Knisely AS, Zaum R, et al. Neonatal haemochromatosis: report of a patient with favourable outcome. Eur J Pediatr 1997; 156(4): 296–8

    PubMed  Article  CAS  Google Scholar 

  77. Van Spronsen FJ, Thomasse Y, Smit GPA, et al. Hereditary tyrosinemia type 1: a clinical classification with difference in prognosis on dietary treatment. Hepatology 1994; 20: 1187–91

    PubMed  Article  Google Scholar 

  78. Pitkanen ST, Salo MK, Heikinheimo M. Hereditary tyrosinaemia type I: from basics to progress in treatment. Ann Med 2000; 32(8): 530–8

    PubMed  Article  CAS  Google Scholar 

  79. Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis 2001; 21(4): 563–71

    PubMed  Article  CAS  Google Scholar 

  80. Mohan N, McKiernan P, Preece MA, et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999; 158Suppl. 2: S49–54

    PubMed  Article  Google Scholar 

  81. Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992; 340(8823): 813–7

    PubMed  Article  CAS  Google Scholar 

  82. Kvittingen EA. Tyrosinaemia: treatment and outcome. J Inherit Metab Dis 1995; 18(4): 375–9

    PubMed  Article  CAS  Google Scholar 

  83. Pronicka E, Rowinska E, Bentkowski Z, et al. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC). J Inherit Metab Dis 1996; 19(2): 234–8

    PubMed  Article  CAS  Google Scholar 

  84. Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998; 21(5): 507–17

    PubMed  Article  CAS  Google Scholar 

  85. Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis 2000; 4(4): 805–14

    PubMed  Article  CAS  Google Scholar 

  86. Kavana M, Moran GR. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohex-anedione. Biochemistry 2003; 42(34): 10238–45

    PubMed  Article  CAS  Google Scholar 

  87. Ahmad S, Teckman JH, Lueder GT. Corneal opacities associated with NTBC treatment. Am J Ophthalmol 2002; 134(2): 266–8

    PubMed  Article  Google Scholar 

  88. Gissen P, Preece MA, Willshaw HA, et al. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. J Inherit Metab Dis 2003; 26(1): 13–6

    PubMed  Article  CAS  Google Scholar 

  89. Jacquemin E, Setchell KDR, O’Connell NC, et al. A new cause of progressive intrahepatic cholestasis: 3-β-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J Pediatr 1994; 125(3): 379–84

    PubMed  Article  CAS  Google Scholar 

  90. Setchell KDR, Suchy FJ, Welsh MB, et al. Delta4-3-oxosteroid 5beta-reductase deficiency described in identical twins with neonatal hepatitis: a new inborn error in bile acid synthesis. J Clin Invest 1988; 82(6): 2148–57

    PubMed  Article  CAS  Google Scholar 

  91. Setchell KD, Schwarz M, O’Connel NC, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998; 102(9): 1690–703

    PubMed  Article  CAS  Google Scholar 

  92. Jacquemin E, Gerhardt M, Cresteil D, et al. Long term effects of bile acid therapy in children with defects of primary bile acid synthesis: 3-β-hydroxy-C27-steroid dehydrogenase/isomerase and delta4-3-oxosteroid 5β-reductase deficiencies. In: van Berge Henegouwen GP, Keppler D, Leuschner U, et al., editors. Biology of bile acids in health and disease. Dordrecht: Kluwer Academic Publishers, 2001: 278–824

    Google Scholar 

  93. Daugherty CC, Setchell KDR, Heubi JE, et al. Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (delta4-3-oxosteroid 5beta-reductase deficiency). Hepatology 1993; 18(5): 1096–101

    PubMed  Article  CAS  Google Scholar 

  94. Suchy FJ. Bile acids for babies? Diagnosis and treatment of a new category of metabolic liver disease. Hepatology 1993; 18(5): 1274–7

    PubMed  Article  CAS  Google Scholar 

  95. Clayton PT. Inborn errors presenting with liver dysfunction. Semin Neonatol 2002; 7(1): 49–63

    PubMed  Article  Google Scholar 

  96. Horslen SP, Fox IJ. Hepatocyte transplantation. Transplantation 2004; 77(10): 1481–6

    PubMed  Article  Google Scholar 

  97. Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of the Crigler-Najjar syndrome type 1 with hepatocyte transplantation. N Engl J Med 1998; 338(20): 1422–6

    PubMed  Article  CAS  Google Scholar 

  98. Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003; 111 (6 Pt 1): 1262–7

    PubMed  Article  Google Scholar 

  99. Sokal EM, Smets F, Bourgois A, et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation 2003; 76(4): 735–8

    PubMed  Article  Google Scholar 

  100. Siddhartha SG, Takahashi M, Thummala NR, et al. Liver-directed gene therapy: promises, problems and prospects at the turn of the century. J Hepatol 2000; 32Suppl. 1: 238–52

    Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Affiliations

  1. Paediatric Hepatology Unit, Hôpital Bicêtre-Assistance Publique-Hôpitaux de Paris, Cedex, France

    Dominique Debray

  2. Paediatric Intensive Care Unit, Hôpital Bicêtre-Assistance Publique-Hôpitaux de Paris, Cedex, France

    Nadya Yousef & Philippe Durand

Authors
  1. Dominique Debray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadya Yousef
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philippe Durand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominique Debray.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Debray, D., Yousef, N. & Durand, P. New Management Options for End-Stage Chronic Liver Disease and Acute Liver Failure. Pediatr-Drugs 8, 1–13 (2006). https://doi.org/10.2165/00148581-200608010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200608010-00001

Keywords

  • Bile Acid
  • Hepatic Encephalopathy
  • Transjugular Intrahepatic Portosystemic Shunt
  • Continuous Renal Replacement Therapy
  • Acute Liver Failure